Blocking IGF1 Receptor Reduces Chronic Migraine Pain and CGRP Levels in Mice
Blocking the IGF1 receptor with picropodophyllin alleviated both baseline hypersensitivity and acute pain attacks in a chronic migraine mouse model, while reducing CGRP and c-Fos expression — identifying IGF1/IGF1r signaling as a new therapeutic target.
Quick Facts
What This Study Found
IGF1r antagonist picropodophyllin alleviated chronic migraine-related pain behaviors and reduced CGRP and c-Fos expression in the trigeminal nucleus caudalis, identifying IGF1/IGF1r signaling as a contributor to chronic migraine.
Key Numbers
NTG-induced chronic migraine model; IGF1/IGF1r pathway targeted; pain relief and autophagy restoration demonstrated.
How They Did This
Chronic migraine induced in mice by repeated nitroglycerin (NTG) injections. Assessed mechanical and thermal sensitivity. Treated with IGF1r antagonist PPP. Measured IGF1, phospho-IGF1r, CGRP, c-Fos expression, and autophagy markers in the TNC by immunostaining and Western blot.
Why This Research Matters
Despite anti-CGRP drugs improving migraine treatment, many patients don't respond adequately. IGF1/IGF1r represents an upstream pathway that drives CGRP expression and neuronal sensitization. Targeting this pathway could help patients who don't respond to CGRP-based therapies, offering a complementary or alternative approach to chronic migraine prevention.
The Bigger Picture
Anti-CGRP therapies have been the biggest advance in migraine treatment in decades, but they don't work for everyone. This study identifies IGF1/IGF1r as an upstream regulator of CGRP in chronic migraine, potentially explaining a mechanism driving CGRP overproduction. If IGF1r blockade can reduce CGRP levels at their source, it could provide relief for patients who don't respond to anti-CGRP drugs, and the combination might be even more effective.
What This Study Doesn't Tell Us
Mouse model using nitroglycerin injections — an imperfect model of human chronic migraine. PPP is a research tool compound, not an approved drug. The specific mechanism linking IGF1r signaling to CGRP upregulation wasn't fully delineated. Only mechanical and thermal sensitivity were assessed — migraine involves many other symptoms. No human data.
Questions This Raises
- ?Would IGF1r inhibitors work in chronic migraine patients who don't respond to anti-CGRP therapies?
- ?Is the IGF1/IGF1r pathway specifically activated in human chronic migraine, or is this an artifact of the mouse model?
- ?Could combining IGF1r blockade with anti-CGRP therapy provide superior migraine prevention?
Trust & Context
- Key Stat:
- Reduced CGRP + pain behaviors IGF1r antagonist PPP alleviated both baseline hypersensitivity and acute allodynia while reducing CGRP expression in the trigeminal nucleus — an upstream target for migraine
- Evidence Grade:
- Preliminary — single animal study using a nitroglycerin-induced chronic migraine model. Demonstrates mechanism but no human validation or clinical data.
- Study Age:
- Published in 2024, contributing to the expanding understanding of molecular pathways beyond CGRP in chronic migraine.
- Original Title:
- Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice.
- Published In:
- The journal of headache and pain, 25(1), 156 (2024)
- Authors:
- Wang, Tianxiao, Zhu, Chenlu, Zhang, Kaibo, Gao, Jinggui, Xu, Yunhao, Duan, Chenyang, Wu, Shouyi, Peng, Cheng, Guan, Jisong, Wang, Yonggang
- Database ID:
- RPEP-09488
Evidence Hierarchy
Frequently Asked Questions
What does IGF1 have to do with migraines?
IGF1 (insulin-like growth factor 1) is a growth hormone-like peptide that also plays roles in pain processing. This study found that neurons in the brain's migraine-processing center produce more IGF1 during chronic migraine, which activates its receptor and amplifies pain signals. It also drives up CGRP — the neuropeptide that anti-migraine drugs like Aimovig target. So IGF1 may be an 'upstream switch' that turns on the pain cascade.
Could this lead to new migraine treatments?
Potentially — blocking the IGF1 receptor reduced both pain sensitivity and CGRP levels in mice. This suggests a drug targeting IGF1r could help migraine patients, especially those who don't respond well to existing anti-CGRP therapies. However, IGF1 has many functions throughout the body, so any treatment would need to be carefully targeted to avoid side effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09488APA
Wang, Tianxiao; Zhu, Chenlu; Zhang, Kaibo; Gao, Jinggui; Xu, Yunhao; Duan, Chenyang; Wu, Shouyi; Peng, Cheng; Guan, Jisong; Wang, Yonggang. (2024). Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice.. The journal of headache and pain, 25(1), 156. https://doi.org/10.1186/s10194-024-01864-6
MLA
Wang, Tianxiao, et al. "Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice.." The journal of headache and pain, 2024. https://doi.org/10.1186/s10194-024-01864-6
RethinkPeptides
RethinkPeptides Research Database. "Targeting IGF1/IGF1r signaling relieve pain and autophagic d..." RPEP-09488. Retrieved from https://rethinkpeptides.com/research/wang-2024-targeting-igf1igf1r-signaling-relieve
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.